Sanofi Leadership Shocker: CEO Paul Hudson Exits as Board Pursues Strategic Reset

Sanofi SA’s board delivered a significant market shocker on Wednesday, announcing it will not renew Paul Hudson’s tenure as Chief Executive Officer. Hudson’s departure marks the end of a six-year leadership chapter at the pharmaceutical giant, with his final day set for February 17, 2026. This abrupt executive transition has already rattled investors and sets the stage for a dramatic organizational restructuring as the company battles mounting pressures in its vaccine portfolio and heavy reliance on a single blockbuster drug.

New Leadership and Strategic Reorientation

The Board of Directors has tapped Belén Garijo as Hudson’s successor. Garijo will officially assume her CEO responsibilities following the company’s Annual General Meeting on April 29, 2026, with the board also proposing her appointment as a director. During the interim period, Olivier Charmeil, Executive Vice President of General Medicines, will serve as acting leader to maintain operational continuity.

Garijo brings a compelling resume to tackle Sanofi’s mounting challenges. Her track record includes leadership at Merck KGaA, where she became Chief Executive Officer in 2021, breaking the glass ceiling as the first woman to helm a DAX40 company in Germany. Her stated priorities at Sanofi center on injecting greater rigor into strategic implementation, with particular emphasis on revitalizing the company’s Research & Development engine—strengthening productivity, governance, and innovation capacity.

The Dupixent Dependency Dilemma

Hudson’s six-year tenure was marked by a critical strategic failure: the inability to reduce Sanofi’s overwhelming dependence on Dupixent, its blockbuster eczema treatment. This concentration risk has haunted both management credibility and share performance. Dupixent generated 4.2 billion euros in Q4 2025, representing a robust 32.2% year-over-year surge, yet this success masks a dangerous vulnerability.

The pharmaceutical titan faces an impending cliff: as Dupixent’s patent exclusivity expires, the company remains dangerously exposed. CFO François-Xavier Roger delivered a sobering assessment to Reuters: “We believe that we will not be able to mitigate the impact of the loss of exclusivity for Dupixent as far as sales are concerned. It’s too big to be mitigated.” This frank admission underscores why the board deemed a leadership change necessary.

Vaccine Portfolio Under Pressure

Sanofi’s vaccine division, another critical earnings pillar, is showing troubling signs. Q4 vaccine sales declined 2.5% to 2 billion euros, with weakness spreading across the portfolio. Beyfortus, the respiratory syncytial virus vaccine, posted disappointing results with sales of 686 million euros, down 14.9%. Polio/Pertussis/Hib vaccines fell 9.5% to 551 million euros, partly due to declining birth rates in key markets including China.

The sole bright spot came from influenza and COVID-19 vaccines, which surged 31.5% to 575 million euros, yet this growth fails to offset deterioration elsewhere in the segment. The vaccine business headwinds, combined with Dupixent’s inevitable decline, have created an urgent succession imperative.

The Pipeline Gamble Ahead

Sanofi’s hopes increasingly rest on amlitelimab, positioned as the potential successor to Dupixent’s cash-generation machine. The company reports that trial data demonstrates robust evidence supporting amlitelimab’s effectiveness in treating moderate-to-severe atopic dermatitis in patients aged 12 and above. Whether this molecule can offset the coming revenue storm remains the critical question facing Garijo’s tenure.

Market Response: Sanofi shares tumbled 6.25% to $46.17 during Thursday premarket trading, reflecting investor anxiety over the sudden leadership transition and the company’s unresolved strategic challenges.